Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5151740 | 0.83 | NQO2 (0.39) | SIGMAR1DRD2NAMPTIDO1SCN9A | |
| SCHEMBL5148509 | 0.80 | KDM4A (0.34) | SIGMAR1NAMPTIDO1SCN9ACKS1B | |
| SCHEMBL5148605 | 0.77 | SIGMAR1 (0.43) | SIGMAR1DRD2NAMPTNPSR1IDO1 | |
| SCHEMBL27603550 | 0.75 | SIGMAR1 (0.38) | SIGMAR1DRD2NPSR1IDO1 | |
| SCHEMBL6065295 | 0.75 | IDO1 (0.33) | SIGMAR1DRD2NAMPTIDO1SCN9A | |
| SCHEMBL5151955 | 0.71 | DRD2 (0.39) | SIGMAR1DRD2IDO1SCN9ACYP3A4 | |
| SCHEMBL5148583 | 0.67 | CKS1B (0.37) | SIGMAR1NAMPTCKS1BSKP1SKP2 | |
| SCHEMBL4583683 | 0.67 | POLB (0.65) | SIGMAR1NPSR1IDO1 | |
| SCHEMBL28822145 | 0.67 | CA12 (0.49) | SIGMAR1DRD2NPSR1IDO1 | |
| SCHEMBL375762 | 0.67 | MEN1 (0.48) | SIGMAR1DRD2NAMPTNPSR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7179801-B2 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2007-02-20 | — | — | US | disclosed |
| EP-1392704-B1 | CEPHEM COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2006-02-22 | — | — | EP | disclosed |
| US-20040248875-A1 | Cephem compounds | ASTELLAS PHARMA INC. (JP) | 2004-12-09 | — | — | US | disclosed |
| EP-1392704-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002090364-A1 | CEPHEM COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248875-A1 | Cephem compounds | CEP170, C1S, SLC7A1 | SIGMAR1 620/4885DRD2 1184/4885NAMPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.